Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Efficacy of A New Crosslinked Hyaluronan Gel in the Prevention of Postoperative Intrauterine Adhesion After Dilatation and Curettage in Women With Delayed Miscarriage: A Prospective, Randomized, Controlled Trial
Brief Summary: Using American Fertility Society classification of intrauterine adhesions, the efficacy of a new crosslinked hyaluronan gel in reducing intrauterine adhesion formation after dilatation and curettage for delayed miscarriage in women without previous dilatation and curettage was examined.


Options:
A: Inclusion Criteria:

* bleeding and contractions during pregnancy

Exclusion Criteria:

* women with known allergy to misoprostol,
* a uterine size more than 12 weeks of gestation,
* suspected ectopic pregnancy,
* unstable hemodynamic status and chock,
* signs of pelvic infection and/or sepsis.
B: The inclusion criteria:

* Patients to be female, aged 18-45 years
* Without previous dilatation and curettage
* Undergoing dilatation and curettage for the current delayed miscarriage
* All participants should be with normal liver/rental function and without systemic disease
* Agree to use adequate forms of contraception throughout the study
* Be in good compliance with the follow-up examination according to the study protocol.

The exclusion criteria:

* Known/suspected intolerance or hypersensitivity to hyaluronan or its derivatives
* Genital tract malformation
* Inflammation of genital tract or pelvic cavity, clinical evidence of cancer in genital tract
* Suspected genital tuberculosis
* Abnormal blood coagulation
* Medical histories of peripheral vascular disease, alcohol/drug abuse, and mental illness
* Acute or severe infection
* Autoimmune diseases.
C: Inclusion Criteria:

* past or present history of vaginal bleeding during pregnancy
* open cervical os
* evidence of incomplete abortion with substantial debris in the uterus (if using ultrasound)
* surgical evacuation of the uterus would be advised as course of action if misoprostol was not available
* generally in good health
* woman lives or works within one hour of study site
* woman willing to provide contact information for follow up purposes
* informed consent given

Exclusion Criteria:

* contraindications to study drug
* uterine size larger than 12 weeks LMP
* signs of severe infection
D: Inclusion Criteria:

* Uterine size no larger than 12 weeks LMP at time of presentation for care.
* Past or present history of vaginal bleeding during pregnancy.
* Open cervical os.
* If ultrasound used evidence of incomplete abortion with substantial debris in the uterus.
* All women would have been advised to have surgical evacuation of the uterus if misoprostol was not available.
* General good health.
* Willing to provide contact information for purposes of follow-up.
* Also in Egypt: 21 years of age or over or parental permission (there is no minimum age requirement in Niger, Mauritania and Senegal).

Exclusion Criteria:

* Contraindications to study drug
* Signs of severe infection, defined as at least one of the following: 1) foul smelling discharge, 2) fever \> 38 degrees C , 3) uterine tenderness
* Hemodynamic disturbances (pulse \>110/min and systolic bp \<100)
* Have an IUD in place; (the IUD may be removed making the woman eligible)
* Suspected ectopic pregnancy

Answer: B